-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...
More »SEARCH RESULT
Total Matching Records found : 56
New hepatitis cure far too costly -Martin Khor
-Asia News Network A controversy is brewing over a new cure for hepatitis C because it is extremely expensive and patients in middle-income countries like Malaysia will find it way beyond their budget. There are an estimated 400,000 Malaysians with hepatitis C, but this is probably a significant under-estimate since many people are not aware that they have the virus. Worldwide, 170 million people live with the hepatitis C virus (HCV), and every...
More »Jumping a red light may soon cost you Rs 5,000; cellphone use Rs 4,000 -Dipak K Dash
-The Times of India NEW DELHI: If you jump a traffic light, drive on the wrong side of the road, refuse to snap on the seat belt or obstruct emergency vehicles, you may soon have to cough up a fine of Rs 5,000. And if you repeat these offences, the penalty could climb to Rs 10,000 and even Rs 15,000, your licence could be suspended and you may be packed off...
More »Defending India’s patent law-Prabha Sridevan
-The Hindu No one can attack India's well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) laws have been the subject of sharp criticism recently. Now, there is talk of the government invoking emergency provisions with regard to Dasatinib, a cancer drug. The decibel level may go up several notches. Let us look...
More »Outside the patent monopolies -Ritu Kamal
-The Indian Express India's role in pharmaceutical patent wars has broadened access to healthcare. Recently, there were rumours that the United States Trade Representative (USTR) was getting ready to announce "trade enforcement actions" or sanctions against India over its intellectual property rights regime. The Obama administration has been under pressure from the US Chamber of Commerce and lobby groups, like the Pharmaceutical Research and Manufacturers of America, to take a tough stance...
More »
